Filing Error Slices Nearly Two Years Off Roche’s UK Lucentis Protection
Firms Warned To Take Care When Paying SPC Fees
Executive Summary
A ruling by the High Court should act as a warning to companies applying for supplementary protection certificates in the UK that they must make sure that the fees are paid for the full duration of the SPC, otherwise they could get a nasty surprise when it expires earlier than expected.
You may also be interested in...
Samsung Bioepis Adds To Biogen Collaboration
Samsung Bioepis and Biogen have agreed a marketing deal for ‘next generation’ biosimilars aflibercept and ranibizumab in the US, Canada, Europe, Japan and Australia, as well as providing an option for Biogen to extend its existing deal to market anti-TNF biosimilars adalimumab, etanercept and infliximab in Europe and adding a further option for rights to sell these three biosimilars in China.
Denmark Planning To Impose Drug Stockpiling Obligations From July
A new bill is intended to address the increase in medicine supply problems in Denmark in recent years.
National Drug Stockpiles Create ‘False Sense Of Security’
The generics and biosimilars industry body Medicines for Europe says disparate national stockpiling requirements are not a solution to shortages and can bring “significant risks” for the supply chain and access to medicines.